Related Experiment Video
Updated: Feb 25, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms
1Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Abstract:
Deregulation of the cytokine-receptor signaling pathway plays a significant role in tumorigenesis. Such deregulation is frequently caused by alterations in the genes involved in the signaling pathway. At the end of 2013, recurrent somatic mutations in the calreticulin (CALR) gene that encodes a molecular chaperone were identified in a subset of patients with Philadelphia-chromosome negative myeloproliferative neoplasms (MPN). The present review focuses on the role of CALR mutations in the oncogenic transformations observed in MPN. All the CALR mutations were found to generate a + 1 frameshift in the reading frame on exon 9, which encodes the carboxy (C)-terminus end of CALR, and thus conferred a common mutant-specific sequence in all the CALR mutants. The mutant CALR (but not the wild-type) constitutively activates the thrombopoietin (TPO) receptor, myeloproliferative leukemia protein (MPL), even in the absence of TPO to induce cellular transformation. Preferential interaction between the mutant CALR and MPL is achieved by a presumptive conformational change induced by the mutant-specific C-terminus domain, which allows N-domain binding to MPL. Even though mutant CALR is expressed on the cell surface and is secreted out of cells, it only presents autocrine capacity for MPL activation. These findings define a novel molecular mechanism by which the mutant molecular chaperone constitutively activates the cytokine receptor to induce cellular transformation.
Insights
Mutations in the calreticulin (CALR) gene drive myeloproliferative neoplasms (MPN) by constitutively activating the thrombopoietin (TPO) receptor, MPL. This discovery reveals a new mechanism of cytokine receptor activation in cancer.
Area of Science:
- Molecular Biology
- Oncology
- Hematology
Background:
- Cytokine-receptor signaling pathway deregulation is crucial in tumorigenesis.
- Alterations in signaling pathway genes often cause deregulation.
- Calreticulin (CALR) gene mutations were identified in Philadelphia-chromosome negative myeloproliferative neoplasms (MPN) in late 2013.
Purpose of the Study:
- To review the role of CALR mutations in oncogenic transformations in MPN.
- To elucidate the molecular mechanism of CALR-mediated MPL activation.
- To understand how mutant CALR induces cellular transformation.
Main Methods:
- Review of existing literature on CALR mutations and MPN.
- Analysis of the structural and functional consequences of CALR mutations.
- Investigation of the interaction between mutant CALR and the TPO receptor (MPL).
Main Results:
- All identified CALR mutations cause a +1 frameshift in exon 9, leading to a common mutant-specific C-terminus sequence.
- Mutant CALR constitutively activates MPL independently of TPO, inducing cellular transformation.
- Mutant CALR preferentially interacts with MPL via a conformational change, enabling N-domain binding.
Conclusions:
- Mutant CALR activates the MPL receptor through a novel mechanism involving its unique C-terminus.
- This aberrant activation of MPL by mutant CALR is a key driver of oncogenesis in a subset of MPN patients.
- The findings highlight a new molecular pathway in cytokine receptor-driven cancers.
Related Concept Videos
Abnormal Proliferation
Differentiation of Common Myeloid Progenitor Cells
The Intrinsic Apoptotic Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

